BETHESDA, Md., Sept. 16, 2016 -- The Cystic Fibrosis Foundation today announced the official opening of a new, one-of-a kind research facility in Lexington, Mass. Operated by Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), an affiliate of the CF Foundation, the lab is designed to identify and test potential therapies for rare and common mutations of cystic fibrosis, with the ultimate goal of bringing new treatments to people living with the disease.
CF is a complex, fatal disease that affects about 30,000 adults and children in the United States and 70,000 people worldwide. It is caused by more than 1,700 genetic mutations in the cystic fibrosis transmembrane conductance regulator (
“Our goal with the new research lab is to speed the development of new treatments for all people with cystic fibrosis,” said William Skach, M.D., senior vice president for research affairs at the CF Foundation. “The lab will provide a unique bridge to fill the gap between academic discovery and the pharmaceutical industry in advancing CF therapies.”
Building on CFFT's expertise in
The team also will continue to screen promising compounds in order to identify the ones that hold the greatest potential for correcting CFTR mutations.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The CF Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of CF Foundation support. Based in Bethesda, Md., the CF Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a
Laurie Fink, national director of media relations: 301-841-2602; firstname.lastname@example.org